<DOC>
	<DOCNO>NCT02120547</DOCNO>
	<brief_summary>To determine whether CVC exposure alter subject impaired hepatic function , compare subject normal hepatic function . The result help guide clinical use CVC patient hepatic impairment , determine extent PK change , , identify potential need dose adjustment CVC population .</brief_summary>
	<brief_title>Phase 1 Study Multiple-Dose Pharmacokinetics Cenicriviroc Subjects With Mild Moderate Hepatic Impairment</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<mesh_term>TAK-652</mesh_term>
	<criteria>Males nonpregnant , nonlactating female age 1865 Weight ≥ 50.0 kg BMI 18.0 40.0 kg/m2 Able participate , willing give write informed consent comply study restriction Subjects hepatic impairment stable liver disease ( Child Pugh A Child Pugh B ) Pregnant lactate woman male partner woman pregnant lactate Uncontrolled treat untreated hypertension ( systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 105 mmHg ) QTcF &gt; 450 msec male &gt; 470 msec female Screening Day 1 Donation loss blood 350 mL within 60 day prior screen Any evidence progressive liver disease within last 4 week subject hepatic impairment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Liver Insufficiency</keyword>
	<keyword>Hepatic impairment</keyword>
</DOC>